Toggle Nav
Close
  • Menu
  • Setting

Anti-NaPi2b/SLC34A2 Antibody (Lifastuzumab vedotin)

Catalog No.
F1439
Anti-NaPi2b/SLC34A2 Antibody (Lifastuzumab vedotin)
Grouped product items
SizePriceStock Qty
100ug
Please inquire
Ship with 3-5 days
1mg
Please inquire
Ship with 3-5 days
For scientific research use only and should not be used for diagnostic or medical purposes.

Tel: +1-832-696-8203

Email: [email protected]

Worldwide Distributors

Background

Lifastuzumab vedotin (LIFA, DNIB0600A, RG-7599) is an antibody-drug conjugate (ADC) consisting of a humanizedAnti-NaPi2b Lifastuzumab vedotin is a monoclonal antibody and the antimitotic cytotoxic agent monomethyl auristatin E (MMAE). Lifastuzumab vedotin is used to treat platinum-resistant ovarian cancer.

Quality Control

Quality Control & DataSheet

View current batch:
 

M.Wt

145 kDa

Shipping

Dry ice

Cas No.

1401812-88-1

Storage

-80°C

Expiration Date

2 years

Form

Liquid

Concentration

See label

Reconstitution

For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.

Host

CHO

Alternative Names

NAPI3B, RG-7599

Buffer System

100 mM Pro 20 mM Arg pH 5.0. No preservative!

Target Accession

O95436

Reactivity

Human

Conjugation

MMAE

Clonality

Monoclonal

Purification

Protein A

Isotype

IgG1

Application

ELISA, FACS, Kinetics, Functional assay, Animal Model

Biological Activity

The drug-to-antibody ratio (DAR) of the Anti-NaPi2b / SLC34A2 Reference Antibody (Lifastuzumab vedotin) is 3.7.

Target

NaPi2b / SLC34A2

Note

Please avoid freeze-thaw cycles.